Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

Background The aim of this study was to evaluate the public health and economic impact of the COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.Research design and methods A combined cohort Markov decision tree model estimated the cost-effectivenes...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Expert Review of Vaccines
Subjects:	COVID-19 SARS-CoV-2 vaccine booster cost-effectiveness Japan
Online Access:	https://www.tandfonline.com/doi/10.1080/14760584.2024.2323133
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production
by: Beatriz Castro-Robles, et al.
Published: (2025-01-01)

Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom
by: Cale Harrison, et al.
Published: (2024-12-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer
by: K.L. Juliëtte Schmidt, et al.
Published: (2024-12-01)

Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01)

Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies
by: Nan Huo, et al.
Published: (2024-12-01)

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
by: Frances Priddy, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024-12-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024-12-01)

Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
by: Anja Rosdahl, et al.
Published: (2024-12-01)

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
by: Guiqiang Wang, et al.
Published: (2025-12-01)

Genomic characteristics, disease outcome and heterologous vaccine effectiveness among cases with SARS CoV-2 infection
by: Rowan Abuyadek, et al.
Published: (2024-11-01)

Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety
by: Esmat Malek, et al.
Published: (2024-11-01)

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
by: Haruka Maeda, et al.
Published: (2024-12-01)

Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore
by: Karan Thakkar, et al.
Published: (2024-12-01)

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia
by: Nadine Al Akoury, et al.
Published: (2025-12-01)

Modeling the potential public health impact of different vaccination strategies with an adapted vaccine in South Africa
by: Nadine Al Akoury, et al.
Published: (2024-12-01)

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies
by: Abundio Balgos, et al.
Published: (2024-12-01)

Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series
by: Maris Taube, et al.
Published: (2025-01-01)

Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies
by: Ching-Wen Hou, et al.
Published: (2025-01-01)

Strategi Komunikasi Pemerintah Provinsi di Indonesia Dalam Program Vaksinasi Booster Melalui X
by: Yohanes Thianika Budiarsa, et al.
Published: (2024-12-01)

Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines
by: Luísa Vilela, et al.
Published: (2024-11-01)

Recent developments in the therapeutics of SARS-CoV-2 infection
by: Priyanka Nagu, et al.
Published: (2024-12-01)

Strategic Health Diplomacy: An Indonesia’s Approach in Securing COVID-19 Booster Vaccine Supplies
by: Deasy Silvya Sari, et al.
Published: (2024-06-01)

Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study
by: Nayab Batool Rizvi, et al.
Published: (2024-11-01)

Boosters in academic discourse: contrastive analysis concerning their use in theses from the fields of social sciences and natural sciences
by: Francisco J. Álvarez-Gil, et al.
Published: (2024-11-01)

Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial
by: Mohammad Hossein Fallah Mehrabadi, et al.
Published: (2024-11-01)

BNT162b2 versus mRNA-1273 mRNA COVID-19 vaccines as the third booster for the patients with underlying cancer
by: Amnuay Kleebayoon, et al.
Published: (2023-12-01)

Mushroom β-glucan and polyphenol formulations as natural immunity boosters and balancers: nature of the application
by: Maja Kozarski, et al.
Published: (2023-03-01)

Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platformResearch in context
by: Jennifer L. Nguyen, et al.
Published: (2025-01-01)

A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines
by: Mary Bausch-Jurken, et al.
Published: (2024-12-01)

Clinical Summary of 186 Cases of Orbital Autologous Fat Injection Transplantation Safely Implemented by Boosters
by: LIU Ping, et al.
Published: (2024-10-01)

Comparative analysis of COVID-19 vaccine booster dose (VBD) acceptance among trainees and students of health professions in Bangladesh
by: Debendra Nath Roy, et al.
Published: (2024-11-01)

Frequency and determinants of acceptance of COVID-19 vaccine booster dose among health care providers: a cross-sectional study
by: Nagat Ibrahim, et al.
Published: (2024-11-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

ATTITUDES TOWARD COVID-19 BOOSTER DOSE VACCINES ACCEPTANCEAMONG HEALTHCARE STUDENTS, KARACHI: A CROSS-SECTIONALANALYSIS
by: Arif Ali, et al.
Published: (2024-12-01)

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers
by: Leire Fernández-Ciriza, et al.
Published: (2025-01-01)